[Skip to Content]
[Skip to Content Landing]
April 1992

Malignant Melanoma: Who Shall Live and Who Shall Die?

Author Affiliations

University of British Columbia Division of Dermatology 855 W 10th Ave Vancouver, British Columbia Canada V5Z 1L7

Arch Dermatol. 1992;128(4):537-542. doi:10.1001/archderm.1992.01680140117016

In 1991, it was estimated that, in the United States, there were over 6500 deaths from malignant melanoma (MM). There are many things about the biology of MM and its interaction with the host's immune system that we do not understand. Yet, we have come a long way—5-year survival has increased from 43% during the 1930s to greater than 80% by the mid-1980s. Many MM investigators have sought the Holy Grail, a factor or group of factors that would allow for the accurate prognostication of disease behavior in the majority of patients.

The study of prognostic factors is important not only for a better understanding of the biologic behavior of MM but also for the optimal management of these patients and for the design and evaluation of therapeutic trials. In the past two decades, many clinical, histologic, immunologic, and cytometric factors have been reported to influence the prognosis of patients